Theseus Pharmaceuticals, Inc. (THRX): Price and Financial Metrics
GET POWR RATINGS... FREE!
THRX Stock Price Chart Interactive Chart >
THRX Price/Volume Stats
|Current price||$6.99||52-week high||$24.54|
|Prev. close||$7.17||52-week low||$6.73|
|Day high||$7.20||Avg. volume||69,101|
|50-day MA||$10.33||Dividend yield||N/A|
|200-day MA||$0.00||Market Cap||270.53M|
Theseus Pharmaceuticals, Inc. (THRX) Company Bio
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-variant inhibitor for activating and resistance mutations of the KIT kinase or a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors (GIST), a type of cancer characterized by oncogenic activation of KIT. The company also develops fourth-generation EGFR inhibitor that is active against C797S, an EGFR mutation that causes resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Most Popular Stories View All
THRX Latest News Stream
|Loading, please wait...|
THRX Latest Social Stream
View Full THRX Social Stream
Latest THRX News From Around the Web
Below are the latest news stories about Theseus Pharmaceuticals Inc that investors may wish to consider to help them evaluate THRX as an investment opportunity.
Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced that Tim Clackson, Ph.D., President and Chief Executive Officer of Theseus, will participate in a virtual fireside chat for the 11th Annual SVB Leerink Global Healthcare Conference, taking place February 14-18, 2022.
Theseus Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for THE-630 for the Treatment of Advanced Gastrointestinal Stromal Tumors (GIST)
Theseus Pharmaceuticals, Inc. (Theseus) (NASDAQ: THRX), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to the company's lead candidate THE-630, a small-molecule oral pan-variant KIT inhibitor, for the treatment of patients with advanced gastrointestina
Recently IPOed biopharmaceutical company Theseus Pharmaceuticals <
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
No summary available.
THRX Price Returns